Advertisements

Назонекс

Quick links to important sections

Назонекс

Selected form

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Назонекс

Property Description
Active ingredient Mometasone Furoate
Form Aqueous Suspension Nasal Spray
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Anti-inflammatory and anti-allergic action
Origin Synthetic

Назонекс: Defining the Medicinal Entity and Pharmacological Class

Назонекс is the trade name for a pharmaceutical preparation whose active substance is Mometasone Furoate, a potent synthetic glucocorticoid. This substance is classified within the corticosteroid pharmacological class, confirming its fundamental role as a powerful anti-inflammatory and anti-allergic agent. The active compound, typically administered as Mometasone Furoate Monohydrate, is a fluorinated derivative, confirming its synthetic origin. This drug exhibits a high affinity for glucocorticoid receptors, which is the basis for its powerful anti-inflammatory action.

Composition and Form: The Intranasal Aqueous Suspension

The signature format of Назонекс is a metered-dose Nasal Spray, specifically formulated as an Aqueous Suspension designed for precise intranasal application. This delivery system focuses the drug directly onto the nasal mucosa where its effect is needed. Назонекс is a single-ingredient product, containing only Mometasone Furoate in a water-based vehicle. This specialized formulation is optimized for topical application to ensure local efficacy. This topical route results in minimal systemic absorption, thereby maximizing local benefits.

General Purpose: Anti-inflammatory and Anti-Allergic Function

The primary general purpose of this preparation is to provide comprehensive and sustained anti-inflammatory and anti-allergic effects within the nasal passages. This synthetic glucocorticoid mechanism allows the drug to substantially reduce the underlying inflammation, swelling, and irritation by inhibiting the cellular production of pro-inflammatory mediators. The benefit of this localized action is to manage the core causes of chronic irritation and allergic symptoms, offering targeted relief for nasal symptoms.

Regulatory References

  1. Mometasone Furoate Summary of Product Characteristics (SmPC)
  2. DailyMed Label: NASONEX (Mometasone Furoate) Nasal Spray
Advertisements

What side effects are possible with Назонекс?

Possible Side Effects and Safety Information

Official Adverse Reactions and Frequency

The safety profile for Назонекс (Mometasone Furoate Nasal Spray) is based on regulatory data, detailing both common and less frequent reactions. Adverse reactions are classified according to official frequency standards.

Classification Adverse Reaction Body System (SOC)
Common (1 in 10 to 1 in 100) Epistaxis (Nosebleed), Headache, Nasal/Throat Irritation Respiratory, Nervous
Uncommon (1 in 100 to 1 in 1,000) Pharyngitis Respiratory
Very Rare (< 1 in 10,000) Anaphylactic reaction, Angioedema Immune System
Frequency Not Known Glaucoma, Cataracts, Nasal septum perforation Eye, Respiratory

Serious Safety Considerations

As a glucocorticoid, the medication carries risks associated with long-term use. Potential serious adverse events documented through regulatory surveillance include the development of Glaucoma or Cataracts, and Nasal septum perforation. The potential for systemic effects, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, is also listed as a risk, particularly with extended exposure.

Safety Constraints and Specific Populations:

  • Pediatrics: Regulatory documents note the risk of growth velocity reduction in children using intranasal corticosteroids.
  • Infections: Use requires caution in patients with untreated local or systemic infections, including active or quiescent tuberculosis.
  • Immune Status: Patients transitioning from systemic corticosteroids must be monitored for signs of adrenal insufficiency due to potential immunosuppression risk.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Acute Overdose Risk (Single Event)

An acute overdose (using too much medication in a single instance) of mometasone furoate nasal spray is generally not expected to cause life-threatening symptoms due to the medication’s low absorption into the bloodstream. In these situations, medical observation is typically the only action required.

Chronic Overdose Risk (Long-Term Misuse)

The primary concern related to overuse is chronic overdose, which involves administering higher-than-recommended doses over an extended period. Prolonged use of excessive doses of any corticosteroid can lead to systemic effects, including the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis controls the body’s natural production of steroid hormones.

When to Seek Medical Attention

  • Emergency Symptoms: Seek immediate emergency medical attention if you experience signs of a severe allergic reaction (such as hives, difficulty breathing, or swelling of the face/throat). While rare, these symptoms require urgent care.
  • Signs of Chronic Overuse: Contact your prescribing healthcare provider promptly if you notice potential signs of long-term steroid use, such as unusual weakness, chronic fatigue, nausea, vomiting, or loss of appetite, as these may indicate HPA axis suppression.
  • Management: If HPA axis suppression is confirmed, a healthcare professional will supervise the gradual reduction of the medication's dose to allow the body's natural hormone production to recover. Do not stop using the medication suddenly without medical guidance.
Advertisements

Therapeutic Uses of Назонекс

Назонекс (mometasone furoate) is an established nasal spray indicated for the management of symptoms associated with nasal allergies and inflammation.

What Назонекс Treats: Main Uses and Benefits

The medication is approved to address symptoms such as nasal congestion, sneezing, runny nose, and itchy nose. These symptoms are often associated with conditions like seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis, which are triggered by allergens such as pollen, dust mites, or pet dander. It is also utilized in certain scenarios for addressing nasal polyps in adults. The main benefit a patient receives is relief from bothersome nasal symptoms, which may assist patients in achieving a greater level of daily comfort.

It is important to understand the medicine's approved uses for safe and effective symptom management.


Quick Fact: Relief for Allergy Symptoms The medication works to provide temporary relief of the symptoms of nasal inflammation.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Nasonex? (Mometasone Furoate)

Official regulatory information defines patient eligibility through specific contraindications and age-based rules. The medication is contraindicated for patients with a known hypersensitivity to Mometasone Furoate or any excipients. Use is also strictly prohibited in patients with recent nasal trauma or surgery until healing is complete, and those with an untreated localized nasal infection, such as Herpes simplex.


Age-Specific Eligibility

Indication Minimum Approved Age
Allergic Rhinitis 2 years of age
Nasal Polyps 18 years of age

Restricted or Conditional Use

Use is not established for children under two years of age for any condition. Additionally, patients with active systemic infections, such as tuberculosis, or pre-existing conditions like glaucoma or cataracts, require caution and medical review. For pregnancy and lactation, use is not recommended unless the potential benefit outweighs the risk; exposed infants may require monitoring for hypoadrenalism.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Mometasone Furoate Nasal Spray is defined by two principal patterns: one pharmacokinetic and one pharmacodynamic.

Metabolic Pharmacokinetic Interactions

Mometasone Furoate is metabolized by the CYP3A4 enzyme system. Co-treatment with strong CYP3A4 inhibitors is expected to inhibit this metabolic process, resulting in a documented increase in the systemic exposure (plasma concentration) of Mometasone Furoate. Medicinal products explicitly documented to cause this interaction, or expected to, include Ketoconazole and Cobicistat-containing products. This interaction is classified as a restriction that requires careful assessment before use, with constraints related to monitoring for potential systemic corticosteroid effects.

Additive Pharmacodynamic Interactions

The co-administration of this nasal spray with other corticosteroids (such as oral, inhaled, or topical formulations) is noted in regulatory documents to present an additive pharmacodynamic risk. This is due to the combined total corticosteroid load, which may increase the risk of systemic corticosteroid effects.

Official Findings and Constraints

A specific interaction study with the antihistamine Loratadine found no clinically significant interaction and no alteration in Mometasone Furoate systemic exposure. No mandatory timing-based separation rules are documented in the official prescribing information for any interacting substance.

Advertisements

Mechanism of Action

Genomic Suppression of Inflammatory Signaling

The mechanism begins when Mometasone Furoate binds to the high-affinity, intracellular Glucocorticoid Receptor (GR) within target cells in the nasal lining. This activated complex then enters the nucleus to modulate gene transcription. It initiates transrepression to inhibit pro-inflammatory transcription factors, such as NF-κB, while using transactivation to increase the synthesis of anti-inflammatory proteins, including Annexin A1. This genomic action suppresses the cellular machinery that generates inflammatory responses.


Inhibition of Key Inflammatory Mediators

The primary consequence of this genomic activity is the reduction in the production of core inflammatory substances. The mechanism affects the supply of inflammatory signals by suppressing the synthesis of cytokines (e.g., IL-1, TNF-α) and chemokines, and indirectly inhibiting the creation of eicosanoids (prostaglandins and leukotrienes). This suppression of mediators alters vascular permeability and modulates the formation of tissue edema in the nasal mucosa.


Mechanism Constraints on Onset Time

Because the drug's effect relies on altering gene expression and synthesizing new regulatory proteins, the full physiological potential is not immediate. The time required for these molecular processes to complete introduces a mechanism constraint defined by the duration necessary to achieve maximal pathway modulation.

Advertisements

Dosage and Administration Information

Administration Guidelines for Nasonex (Mometasone Furoate)

The following outlines the standard steps for using the Nasonex nasal spray.

Dosing Schedule

The standard application involves actuating the spray into each nostril once daily. The specific dosage varies based on the patient's age and condition.

Population Standard Dosing (Per Nostril) Total Daily Dose
Adults and Adolescents (ge 12 years) 2 sprays once daily 200 mcg
Children (3-11 years) 1 spray once daily 100 mcg

Administration Technique

  1. Preparation: Shake the bottle gently before each use. The pump must be primed before the first use (10 actuations) and reprimed (2 actuations) if left unused for 7 days or more.
  2. Application: Gently clear the nasal passages. Close one nostril, insert the nozzle into the other nostril, and aim the spray slightly away from the center of the nose (nasal septum).
  3. Procedure: While sniffing gently, press down for the required number of sprays and repeat the process in the opposite nostril.

Use Constraints

  • Route: The medication is for intranasal use only. It must not be sprayed into the eyes or mouth.
  • Missed Dose: If a dose is missed, it is typically applied as soon as remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose is skipped.
  • Duration: The bottle must be discarded after the designated number of sprays (e.g., 120 or 140) or after two months following the first opening, whichever occurs first.
Advertisements

Recent Clinical Evidence

Mometasone Furoate Nasal Spray: Recent Clinical Evidence


Efficacy in Allergic Rhinitis

Clinical trials, including multiple randomized, double-blind, placebo-controlled studies, have extensively investigated the use of mometasone furoate nasal spray (MFNS) for the nasal symptoms of seasonal and perennial allergic rhinitis.

Research found that, when compared to placebo, MFNS was associated with statistically significant improvements in key symptom scores, including nasal congestion, sneezing, itching, and runny nose. Improvements in total nasal symptom scores were generally observed across adult and pediatric populations (aged 2 years and older).

Treatment of Nasal Polyps

For the treatment of nasal polyposis (nasal polyps), studies have evaluated the effect of MFNS on polyp size and associated symptoms. Trials in adults (18 years and older) demonstrated that the product, compared to a placebo, was associated with greater reductions in physician-evaluated bilateral polyp grade scores and subject-assessed nasal congestion/obstruction scores over a treatment period of several months.

Safety and Tolerability Profile

MFNS has been noted in clinical reviews to have minimal systemic absorption, with less than 0.1% of the administered dose typically reaching the systemic circulation. This characteristic is considered a contributing factor to its favorable safety profile regarding systemic effects, such as the hypothalamic-pituitary-adrenal (HPA) axis function.

Common adverse events reported in clinical trials were generally mild and localized to the nasal area, primarily including headache, nosebleeds (epistaxis), and throat irritation (pharyngitis).

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Назонекс (FAQ)


Q: What is the difference between Назонекс and regular antihistamine pills?

A: Назонекс (mometasone furoate) is a corticosteroid, which means it works locally in the nose to reduce the underlying inflammation and swelling. In contrast, antihistamines typically work by blocking the effects of histamine throughout the body. Official regulatory data indicates that no clinically significant interactions were observed when this spray was studied alongside the antihistamine Loratadine.


Q: Can children of school age use Назонекс, and if so, how is it different for them?

A: According to official product information, the medication is approved for allergic rhinitis in children as young as 2 years old. However, the regulatory label includes a specific precaution for children using intranasal corticosteroids. There is a potential risk of a reduction in growth velocity, and growth monitoring may be advised.


Q: How is the dose for adults typically different from the dose for adolescents?

A: Based on the official dosing schedules, the standard prescribed dose for allergic rhinitis is generally the same for both adults and adolescents (12 years of age and older).


Q: If I stop using Назонекс suddenly, will my symptoms come back worse (rebound effect)?

A: The medication's mechanism of action is anti-inflammatory and works on the cellular level. This is different from that of nasal decongestant sprays, which are the products typically associated with the risk of 'rebound congestion' or rhinitis medicamentosa if stopped suddenly.


Q: Why is it important to aim the spray away from the nasal septum?

A: Official instructions for use advise this technique, as nasal septal perforation (a hole in the septum) is listed in regulatory documents as a potential safety concern associated with nasal steroids. The technique helps ensure proper application away from the central ridge of the nose.


Q: Does Назонекс affect eye pressure, and if so, how?

A: Official safety constraints list the development of glaucoma (a condition related to increased eye pressure) and cataracts as potential, though rare, safety considerations with the use of nasal corticosteroids. For patients using the spray for extended periods, monitoring of eye health may be advised as a precaution.


Q: Does Назонекс have an effect on growth in children (general concern)?

A: Official safety constraints note the potential for a reduction in growth velocity in children using intranasal corticosteroids. Official guidance emphasizes using the lowest effective dose for the shortest possible duration in children.


Q: Can Назонекс help with non-allergic congestion, or is it only for allergies?

A: The medication is officially indicated for the relief and prevention of symptoms associated with allergic rhinitis (seasonal and perennial) and for the treatment of nasal polyps. Official product information states that this medication is not indicated for treating symptoms caused by conditions such as the common cold.


Q: Is Назонекс considered a preventative treatment or a symptom reliever?

A: According to official product information, the medication is indicated for both the treatment of existing nasal allergy symptoms and the prophylaxis (prevention) of seasonal allergic rhinitis. For prevention, treatment is often initiated 2 to 4 weeks before the expected start of the pollen season.


Q: Is it common to feel a slight stinging or burning sensation right after using Назонекс?

A: The official safety profile lists nasal or throat irritation as a common adverse reaction that can occur. Patient instructions may note that a minor stinging sensation right after use can be expected in some individuals.


Q: Is it normal to have some blood streaks in my mucus when starting Назонекс?

A: Official safety data lists epistaxis, or nosebleed, as a common adverse reaction. This reaction may be experienced as noticeable blood streaks in nasal mucus. Official documents advise seeking medical guidance for frequent or severe nosebleeds.


Q: Does using Назонекс affect my sense of smell or taste?

A: Changes in the sense of smell and changes in taste have been reported as adverse events in postmarketing regulatory experience. These effects are not classified by frequency.


Q: Is Назонекс useful for people who only have seasonal allergies, or is it better for year-round issues?

A: The medication is officially approved and indicated for the treatment of nasal symptoms associated with both seasonal allergic rhinitis (which occurs during specific seasons) and perennial allergic rhinitis (which occurs year-round).


Q: Can Назонекс be used to help clear up sinus infections (general use question)?

A: Official product information states that the medication is contraindicated in patients with an untreated localized nasal infection. The medication is not indicated for treating bacterial, viral, or fungal sinus infections.


Q: What's the difference between Назонекс and other common nasal sprays that aren't steroids?

A: Назонекс is a corticosteroid that acts locally to reduce inflammation. This mechanism differs from non-steroid sprays such as saline rinses, which are for cleansing, or nasal decongestants, which temporarily shrink blood vessels to relieve congestion.


Q: What are the signs that Назонекс might be starting to work for my symptoms?

A: Clinical studies indicate that symptom relief may begin as early as 12 hours after the first application in some patients. However, because the full effect relies on cellular changes, regular use over several days is typically required to achieve the full intended benefit.


Q: Is it possible to become dependent on Назонекс over time?

A: The drug is a corticosteroid with minimal systemic absorption, with typically less than 0.1% of the dose reaching the bloodstream. Due to this minimal absorption, the risk of developing systemic dependence is generally considered low when compared to high-dose systemic corticosteroids.


Q: How do I clean the nozzle of the Назонекс spray device?

A: Instructions for use provide detailed guidance on cleaning the nozzle, which typically involves rinsing it with water and allowing it to air dry before repriming the pump. It is important to refer to the specific instructions provided with the product.


Q: Can Назонекс be used in combination with nasal decongestant sprays (general comparison)?

A: Regulatory guidance may suggest that in cases of severe nasal blockage, a nasal vasoconstrictor (decongestant) may be used for a very short period, such as 2 to 3 days, prior to starting a corticosteroid spray like Назонекс. This practice is intended to allow the steroid to reach the nasal lining more effectively.

Advertisements

How should Назонекс be stored and disposed of?

The nasal spray should be stored in its original container at room temperature, generally not exceeding 25 C (77 F). It is essential to protect the medication from freezing, as this can affect the suspension's efficacy. Keep the spray out of the reach of children.

Condition Recommendation
Temperature Do not store above 25 C (77 F)
Freezing Do not freeze
After First Use Discard the bottle after two months

The bottle should be discarded after the labeled number of sprays (often 120 or 140 actuations), even if some liquid remains. Never keep or use outdated medicine. For disposal of the unused or expired product, always consult your pharmacist or local waste management authority for guidance on proper, safe disposal methods, avoiding disposal in household trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Назонекс found in:

A-Z Index: